As the COVID-19 pandemic unfolded, researchers worldwide scrambled to identify existing drugs that could be rapidly repurposed to combat SARS-CoV-2. Among the many candidates, bromhexine—a well-known mucolytic cough suppressant—emerged as a surprisingly promising contender, not merely for symptom relief but as a potential antiviral agent. Its dual action targeting both the protease TMPRSS2, crucial for viral entry, and the excessive mucus that characterizes severe respiratory disease, positioned it uniquely in the therapeutic landscape. The work of Maggio and colleagues crystallized this potential, laying out a compelling case for why an old, inexpensive over-the-counter remedy deserved a serious look as a front-line weapon against a novel coronavirus.
Understanding Bromhexine: More Than Just a Cough Medicine
Bromhexine is a synthetic derivative of vasicine, an alkaloid from the plant Adhatoda vasica, which has been used in traditional medicine for centuries. Since its introduction in the 1960s, it has been widely prescribed and sold as a mucolytic agent to treat respiratory conditions characterized by thick, stubborn mucus, such as chronic bronchitis and asthma. Its primary mechanism involves depolymerization of mucopolysaccharides in mucus, breaking down the gel-like structure and making secretions easier to cough up. This not only relieves symptoms but also helps to clear the airways, reducing the risk of secondary infections and improving lung function.
However, bromhexine’s story took a dramatic turn in early 2020, when scientists probing the cell entry mechanisms of SARS-CoV-2 realized that the drug had a hidden talent: it is a potent inhibitor of the host protease TMPRSS2. This enzyme is co-opted by the virus to prime its spike protein, a necessary step for fusion with the cell membrane. Because bromhexine had been used for decades with a well-documented safety profile in millions of patients, the idea of repurposing it for COVID-19 offered a tantalizing shortcut through the labyrinth of drug development. Instead of starting from scratch, researchers could leap to clinical testing, and in the words of Maggio et al., “the path from bench to bedside could be measured in weeks, not years.”
“Bromhexine represents a unique opportunity to target both the virus and the host response, making it a dual-threat countermeasure in the fight against COVID-19.”
The TMPRSS2 Connection: Blocking Viral Entry
SARS-CoV-2 enters human cells through a two-step process: the spike protein first binds to the ACE2 receptor, and then must be cleaved by a host protease to trigger membrane fusion. While several proteases can perform this cleavage, TMPRSS2 (transmembrane protease serine 2) is the most efficient and physiologically relevant in the respiratory tract. By inhibiting TMPRSS2, bromhexine effectively slams the door on the virus, preventing it from penetrating the cell even if it has already latched onto ACE2.
This mechanism is analogous to that of camostat mesylate and nafamostat, two other TMPRSS2 inhibitors that received early attention. However, bromhexine offers distinct advantages: it is orally bioavailable, whereas camostat is poorly absorbed and often requires intravenous administration in its active form. Moreover, bromhexine’s metabolite, ambroxol, also retains some inhibitory activity and is itself a well-known mucolytic, creating a sustained effect. Computational and in vitro work by Habtemariam and others confirmed that bromhexine binds directly to the catalytic site of TMPRSS2 with high affinity, lending strong biochemical plausibility to the repurposing hypothesis.
Mucolytic Effects: A Two-Pronged Approach
Beyond its antiviral potential, bromhexine’s classical mucolytic action addresses a critical pathological feature of severe COVID-19. Autopsy studies have revealed that many patients develop extensive mucus plugging in the small airways, contributing to the profound hypoxemia and ventilation-perfusion mismatch that characterize the disease. Thick, tenacious secretions also provide a breeding ground for secondary bacterial infections and can render mechanical ventilation less effective.
By thinning respiratory mucus and enhancing its clearance, bromhexine could help to keep airways open, improve gas exchange, and reduce the likelihood of ventilator-associated complications. This dual mechanism—direct antiviral activity at the point of entry plus symptomatic relief—makes it a more versatile candidate than pure antiviral compounds. Depfenhart et al. highlighted this synergy early in the pandemic, arguing that bromhexine as an add-on therapy could bridge the gap until definitive treatments arrived. For outpatients and even prophylactic settings, the drug’s ability to tame early viral replication while keeping airways clean presented an attractive low-risk, high-reward proposition.
Evidence from Clinical Studies and Expert Reviews
The clinical evidence for bromhexine in COVID-19 has been mixed but instructive. Several randomized controlled trials (RCTs) were launched in 2020–2021, primarily in moderate-to-severe hospitalized patients. A prominent Iranian trial found that adding bromhexine to standard care significantly reduced ICU admission and mortality in hospitalized patients, while a smaller study in India suggested faster clinical recovery and viral clearance. However, other trials, including a large multicenter RCT in Brazil, failed to show a significant benefit, possibly due to late enrollment and advanced disease at the time of treatment.
Al-Kuraishy and colleagues provided a comprehensive review of these conflicting results, noting that bromhexine’s mechanism is most relevant in the early stages of infection when viral replication depends on TMPRSS2-mediated entry. Once the virus has already disseminated and inflammation dominates, inhibiting viral entry may offer little advantage. Timing, dosing, and patient selection therefore emerge as crucial variables. Maggio and fellow researchers emphasized that the drug’s true value may lie in prophylaxis or early outpatient treatment, where it could be taken orally at the first sign of symptoms—or even before exposure—to blunt the initial viral onslaught and prevent progression to severe disease.
- Prophylaxis: Preventative use in high-risk contacts or healthcare workers.
- Early treatment: At symptom onset to reduce viral load and airway congestion.
- Adjunct therapy: In hospitalized patients to manage mucus and reduce secondary infections.
Safety, Tolerability, and Logistical Advantages
One of bromhexine’s greatest strengths is its impeccable safety record. Over more than 50 years of use, it has been associated with only rare and mild adverse effects—mostly transient gastrointestinal upset, headache, or dizziness. It has no known teratogenicity, can be used in children and the elderly, and requires no routine monitoring of liver or kidney function. This contrasts sharply with many experimental antivirals that carry significant toxicity or drug-drug interaction risks.
Equally important in a resource-constrained world, bromhexine is off-patent, cheap, stable at room temperature, and widely available even in low- and middle-income countries. During the pandemic, when high-income nations hoarded novel therapeutics, bromhexine represented an accessible option that could be manufactured locally and distributed without cold chains. Maggio’s team underscored this global health equity angle: repurposing a generic drug could democratize access to early COVID-19 treatment, particularly in settings where expensive biologics and advanced diagnostics remain out of reach.
Challenges, Unanswered Questions, and the Way Forward
Despite its promise, bromhexine faces several hurdles. The most significant is the lack of definitive, large-scale phase III trials specifically designed to test its efficacy in early disease or prophylaxis. Most completed studies were small, underpowered, or focused on hospitalized patients—precisely the population least likely to benefit from a viral-entry inhibitor. There is also ambiguity about optimal dosing: while standard mucolytic doses (8–16 mg three times daily) were used in trials, some pharmacokinetic models suggest higher concentrations may be needed to saturate TMPRSS2 in the respiratory epithelium. Moreover, the drug’s relatively short half-life might necessitate frequent dosing or a sustained-release formulation.
Another challenge is the evolving viral landscape. With the emergence of Omicron and its subvariants, SARS-CoV-2 has shifted its entry mechanism to favor endosomal cathepsin-mediated fusion over TMPRSS2-dependent cell surface fusion in some cell types. This means bromhexine’s antiviral potency could be reduced against newer variants, although its mucolytic benefits would remain undiminished. Nonetheless, as the virus continues to circulate and long COVID becomes a pressing concern, the search for safe, oral, host-directed therapies remains urgent. Bromhexine, with its dual action and unparalleled safety, still holds a place in that conversation—especially if future research focuses on its early use, alone or in combination with other agents.
Conclusion: A Lesson in Pragmatic Repurposing
The story of bromhexine and COVID-19 illustrates both the promise and the pitfalls of drug repurposing in a fast-moving pandemic. Maggio and colleagues provided a thoughtful roadmap, grounded in mechanistic insight and clinical pragmatism, that turned generations of real-world experience into a testable hypothesis. While the definitive proof remains elusive, the body of evidence suggests that this old cough medicine may indeed have a role to play—not as a miracle cure, but as a safe, affordable, and accessible tool in the broader armamentarium against respiratory viral threats. As we prepare for the next pandemic, the lesson is clear: sometimes the most valuable weapons are already hiding in plain sight on pharmacy shelves.